Smither John W
SEC CIK 1559583 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | Dir | 8,760 | — | $40.5K | 3 | 2025-01-07 | 2026-09-04 |
| MBX | MBX Biosciences, Inc. | CFO | 28.0K | — | — | 1 | 2026-08-03 | 2026-08-03 |
| GNLX | GENELUX Corp | Dir | 91.4K | — | $53.6K | 7 | 2023-09-11 | 2026-07-01 |
| ARQT | Arcutis Biotherapeutics, Inc. | CFO | 11.4K | — | — | 1 | 2024-02-13 | 2024-02-13 |
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 16:30 | 2026-09-04 | NAMS | NewAmsterdam Pharma Co N.V. | Smither John W | Dir | S - Sale | $25.32 | -1,600 | 8,760 | -15% | -$40.5K | |
| D | 2026-08-04 08:51 | 2026-08-03 | MBX | MBX Biosciences, Inc. | Smither John W | CFO | A - Grant | $0.00 | +28.0K | 28.0K | New | $0 |
| 2026-07-02 16:35 | 2026-07-01 | GNLX | GENELUX Corp | Smither John W | Dir | S - Sale | $2.91 | -12.0K | 91.4K | -12% | -$34.9K | |
| D | 2026-06-18 19:05 | 2026-06-16 | GNLX | GENELUX Corp | Smither John W | Dir | A - Grant | $0.00 | +28.4K | 103.4K | +38% | $0 |
| D | 2026-01-09 | 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Smither John W | Dir | A - Grant | — | +3,400 | 10.4K | +49% | — |
| D | 2025-08-29 | 2025-08-27 | GNLX | GENELUX Corp | Smither John W | Dir | A - Grant | $0.00 | +22.3K | 75.0K | +42% | $0 |
| D | 2025-01-08 | 2025-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Smither John W | Dir | A - Grant | — | +6,960 | 6,960 | New | — |
| D | 2024-08-05 | 2024-08-01 | GNLX | GENELUX Corp | Smither John W | Dir | A - Grant | $0.00 | +39.5K | 52.7K | +300% | $0 |
| D | 2024-06-07 | 2024-05-29 | GNLX | GENELUX Corp | Smither John W | Dir | P - Purchase | — | +6,250 | 13.2K | +90% | — |
| DM | 2024-02-15 | 2024-02-13 | ARQT | Arcutis Biotherapeutics, Inc. | Smither John W | CFO | A - Grant | — | +11.4K | 11.4K | New | — |
| 2023-09-14 | 2023-09-13 | GNLX | GENELUX Corp | Smither John W | Dir | S - Sale | $20.78 | -900 | 6,920 | -12% | -$18.7K | |
| D | 2023-09-13 | 2023-09-11 | GNLX | GENELUX Corp | Smither John W | Dir | A - Grant | $0.00 | +6,920 | 7,820 | +769% | $0 |
Purchase Sale Sale after option exercise All abbreviations